nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01752205,Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma,0.0030646326819076634,0.0033776537484331653
NCT01737008,"Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck",0.004120662415243898,0.0043027391319595655
NCT01721525,"Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)",0.0021031246196442973,0.00291797261017369
NCT01716416,Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),0.004330809556520053,0.0039728334233701595
NCT02876978,Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma,0.004645839649100154,0.003567811965178491
NCT02817958,Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis,0.002150448981828329,0.003284780408376929
NCT02819752,PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck,0.005161914293263005,0.003664719166422237
NCT02883556,Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin,0.002951764234053799,0.004071888332680397
NCT02852343,One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma,0.003459089387829586,0.002467701512849346
NCT02878655,"Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS",0.002151413908146739,0.002025846227666666
NCT02822482,Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss,0.0038863102394790386,0.003992791868883945
NCT02892786,Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma,0.003668185290367706,0.0035494338390538367
NCT02862678,Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study,0.00352927331453251,0.0030822187876408894
NCT01592721,Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma,0.0040423681770562735,0.004141192978126046
NCT01542931,TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma,0.003922058175624933,0.0033010271685728607
NCT01515137,Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma,0.004025644087437266,0.004336274949412688
NCT01507467,IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck,0.004329405767937948,0.003383565899336988
NCT01561456,Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung,0.003305904345194885,0.004646715738909254
NCT01538381,Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck,0.003982966264244531,0.003594158012428717
NCT02216916,Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy,0.003996186812955998,0.005040055187156876
NCT02255097,Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),0.003948934148853799,0.00446538694905442
NCT02270814,"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",0.004171634041959365,0.00418121112137079
NCT02290145,Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage,0.0026111382282531705,0.003581107224706441
NCT02279459,Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas,0.004003668068715492,0.003054611062080402
NCT02269020,Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx,0.00281834263789801,0.002513634060758524
NCT02296684,Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,0.004096540818974739,0.0028779488907111953
NCT02207439,"A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx",0.0027713278525561083,0.003067714475356248
NCT02277184,"Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",0.0048179609976602535,0.004289327469116531
NCT02277197,Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),0.00455209362149638,0.0038710793685484426
NCT02282371,Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),0.0038031166648619342,0.004380218234656474
NCT02213133,Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas,0.0028583135711500165,0.0037086849886146275
NCT02254044,Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus,0.003876588929428356,0.004049828713632703
NCT02254018,Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck,0.004180447120251001,0.004702671761234423
NCT00566540,"Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer",0.0030943719155583386,0.003279084145870808
NCT00547157,"Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",0.003709543078006019,0.003728515461609323
NCT00596219,Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma,0.0033408235384675446,0.003737710234278865
NCT00519077,Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck,0.003464156681888721,0.0033642338571398906
NCT00588770,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,0.003930111046465575,0.00415855741934534
NCT00530283,PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy,0.0021992815292648355,0.0024236499165737287
NCT00507858,Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer,0.004003668068715492,0.0030404449025211774
NCT00512096,Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis,0.0029682521376821554,0.0027632301783024286
NCT02706691,"Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck",0.00358866419860688,0.0036088466766259486
NCT02739204,Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma,0.0033258049178003044,0.0024650029531466896
NCT02717936,Investigation of Desmoplastic Squamous Cell Carcinoma,0.003265178443341618,0.0026110803455583276
NCT02743832,A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.,0.002588113166007769,0.0035887554471782787
NCT02734537,Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery,0.004044723248267906,0.004330932382789
NCT02784288,Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer,0.002588620009500437,0.002689177247268568
NCT02769520,"Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",0.0039586409071786285,0.0035939238167985443
NCT02778191,Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma,0.0038066748260220176,0.00385929053092017
NCT02765503,Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial,0.0048560322369921435,0.0036516000650975372
NCT02764593,Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,0.003876048728275931,0.004196862951143267
NCT02775006,"Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma",0.0026838556613477125,0.003231547041271172
NCT02775812,"Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",0.0038141294315407995,0.0040433926780566115
NCT03022409,A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),0.004011022925527293,0.003936170787248907
NCT03040999,Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),0.0038813449429176304,0.003781346604545851
NCT03015883,Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma,0.0026909350730653374,0.0037185598206762546
NCT03010553,"Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot",0.0026136226576947853,0.0026732962990594243
NCT03057613,The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck,0.004405713897588527,0.003357763914484131
NCT03083873,Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck,0.002634705451144689,0.00345739479883628
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",0.0025688257008892046,0.0016597367197467064
NCT03024489,Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma,0.003405984435901695,0.00400798320542407
NCT03076281,Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,0.003573808664157757,0.003702412424248442
NCT03082534,Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,0.002733406655081135,0.00289912234472084
NCT00240682,Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR,0.0034717067447797524,0.005164697999906603
NCT00220129,"Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus",0.002322845352317002,0.002631826264749817
NCT00233636,Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck,0.003969082836703078,0.005116654770924818
NCT00251381,Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.,0.0032486482152711965,0.003968989161302608
NCT00229723,IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma,0.003592499663071795,0.003693405511092591
NCT00239200,Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus,0.0027893269599232125,0.0028543760183572173
NCT00210041,Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma,0.0026937810748555945,0.003913654778713418
NCT00268671,Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN),0.004499888943424066,0.004424628462718009
NCT00258310,"Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy",0.003686807135562667,0.0038406992916761376
NCT00257738,MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck,0.005070767940139971,0.0029023804567706248
NCT02381535,Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,0.004288416356280882,0.004284329447149347
NCT02375997,Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer,0.0027814469000053137,0.0029401974275526884
NCT02345330,Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC),0.0040113339496904675,0.003743156648624304
NCT02379039,Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer,0.002536810139166347,0.003267481130021305
NCT02384434,Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma,0.0031923070419496414,0.004085145151572343
NCT02358031,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),0.00378789222131043,0.0037878390078150397
NCT02319044,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",0.003980820112187503,0.0037798233683291275
NCT02325401,Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,0.0038226679084374226,0.003934724356375835
NCT02369458,"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane",0.0036597959195809764,0.0027767587023321775
NCT01301248,Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck,0.0038634352869393565,0.00406945870766309
NCT01312350,Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN),0.0040246589149763624,0.0032719300510054197
NCT01326923,Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer,0.0036433376567877795,0.004192599041725957
NCT01303237,A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004244051006839231,0.004011875027454445
NCT01358097,Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy,0.0033870716340141526,0.0034644885409326346
NCT01334320,"Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma",0.003214455740042326,0.002647148493466861
NCT01361100,Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract,0.002610547390244905,0.0030210006180597516
NCT01316757,"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",0.0038864297591714044,0.003440347777085539
NCT01377298,Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,0.004200240994700687,0.004025794148160243
NCT01332266,E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck,0.0034706045811534183,0.0044073513422694345
NCT01345669,LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,0.0033922456685315855,0.0034731971675805123
NCT01345682,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,0.0034220131819447655,0.004323745410094933
NCT00868088,Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip,0.0025875516894062266,0.002716844660824592
NCT00894413,A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract,0.0028138722382401275,0.0033846387177308974
NCT00855881,Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma,0.0034286281382258023,0.00264163774607812
NCT00865098,Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN),0.0045904374333639855,0.004147640822557089
NCT00896675,Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer,0.0038137640165800918,0.004053674438914884
NCT00805012,Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC),0.005345696562634686,0.005219536166584881
NCT01697800,A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract,0.0028138722382401275,0.0029644989042037187
NCT01636544,Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity,0.0031928722363636862,0.002316566286673499
NCT01602315,A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,0.004350034039639037,0.004489891217776042
NCT01695122,Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,0.003628184753165614,0.004053928574685692
NCT01666431,Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment,0.0029632043277013215,0.003518674837783606
NCT01606566,A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma,0.00451611758759648,0.00503206891877853
NCT01660399,Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy,0.0027372153891580863,0.0027623057619290126
NCT01012258,Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects,0.004421398402057933,0.003795631504569465
NCT01046266,A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma,0.005250621616919325,0.003746959482270675
NCT01086826,Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004630377914443221,0.004247302383560626
NCT01054625,Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN),0.003996135105896889,0.0030563419834436743
NCT01016769,Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC),0.003428593285780868,0.004059761956522037
NCT01044433,Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck,0.004022718308147082,0.003464165095090373
NCT01064479,Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,0.0026999677423208317,0.003398256528294962
NCT01020097,"Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx",0.0026689098485388244,0.003196607355223322
NCT01009203,"Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma",0.0024871245023224044,0.003531840821075697
NCT01009346,A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck,0.004059095468187717,0.004080967465988184
NCT01079546,Human Papillomavirus (HPV) in Squamous Cell Carcinoma of the Head and Neck,0.005081289676976032,0.0030179040479925597
NCT01059643,"A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck",0.0033768195869947524,0.0037065732147023686
NCT01075828,"Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea",0.004501864011215719,0.003353764458203034
NCT01075841,A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck,0.0036726347972389655,0.0030638407535096297
NCT01017224,DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC),0.004012578534273079,0.002715969558165025
NCT02479178,"A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck",0.003883280869163202,0.003270505810700603
NCT02454179,Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma,0.0038997693560392428,0.0050092326121940365
NCT02495064,Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients,0.0035165489103568953,0.003537608360907427
NCT02438995,Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck,0.0036137206938495745,0.004374574714596443
NCT02485548,Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer,0.003669230773157502,0.004529094980425813
NCT00102635,4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC),0.005070767940139971,0.003250390829742004
NCT00195299,Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck,0.002920326416526981,0.002918768103269538
NCT00184028,Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck,0.0035521143383411185,0.004171075790958159
NCT00185835,Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck,0.0036859704194108778,0.0038804129562899836
NCT00173849,The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma,0.0032394380547507867,0.0037687037256114307
NCT00139230,Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004515010964617712,0.004360277338141331
NCT00139269,Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004144492941092153,0.003961113693575259
NCT00139243,"Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck",0.0036759258478101077,0.0047035052226039546
NCT00113347,Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC),0.003397886569152702,0.004147890607331371
NCT00144976,Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma,0.0030044377115032526,0.003625140647623304
NCT00188318,Hardwins - Squamous Cell Carcinoma Head & Neck (Surgery/RT),0.002867425247886894,0.002959544391633146
NCT00198328,Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma,0.0035804597378479223,0.002948887333107667
NCT00198315,Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma,0.0035804597378479223,0.0030024911720751258
NCT02139020,Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients,0.004003668068715492,0.0040177208502926035
NCT02110992,Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck,0.004749820328262037,0.004357058409526141
NCT02131805,Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma,0.0026007166584504785,0.002504981465268095
NCT02131155,LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,0.0033422963996429357,0.0033036238784170903
NCT02163057,Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma,0.004077406804848805,0.003649034307947929
NCT02143622,Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients,0.004736265578457976,0.005287546236419461
NCT02158234,"Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck",0.0034021346542754483,0.004012905406691118
NCT02156180,Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma,0.003460457719575416,0.0032524106334707835
NCT01127737,Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients,0.0022503818450515006,0.0015716276045754977
NCT01179360,Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC),0.003872417066353709,0.0034626903271060753
NCT01154920,"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",0.004373413496196845,0.00407586229240191
NCT01194635,"Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy",0.004090369685514272,0.0043322218470424065
NCT01183065,Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC),0.003501164005778595,0.0033254054357871017
NCT01192815,Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck,0.003781644817469906,0.003445299741793628
NCT01192750,Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab,0.004073608512988326,0.0039128554994512
NCT01151839,A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus,0.0023919840399468408,0.0022251992985237528
NCT01104922,Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,0.004156954451082013,0.004524544548211814
NCT01195922,Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,0.004221418251904484,0.004061452887619401
NCT02057107,"Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",0.0035536364675325858,0.0030132508460948976
NCT02009852,The Role of microRNA-29b in the Oral Squamous Cell Carcinoma,0.0045976649059705135,0.0063784629754422995
NCT02015650,Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck,0.003848210746202199,0.004057478982314966
NCT02083692,Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,0.0035728366638781224,0.0034650619168520827
NCT02058849,Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck,0.003778012442048275,0.0034738986511954856
NCT02088515,Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma,0.0028745644575749957,0.002673602079450254
NCT02095912,Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients,0.0031931209488360113,0.0022401812617424345
NCT00964977,Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.,0.002061568295048833,0.0036986826986249886
NCT00998192,A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung,0.0029817437393264107,0.003764408726116518
NCT00942734,Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma,0.005204393411355872,0.0036957161324574967
NCT00910117,Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC),0.003906485802256542,0.003761642966425528
NCT00966472,Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC,0.002812867231127383,0.003617396142183648
NCT00934518,Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma,0.003300486294433905,0.0033805401045600065
NCT00933387,A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma,0.003177471117224762,0.004226858631537738
NCT00995293,Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial,0.0035004394294005136,0.0038510395870295215
NCT00906360,"Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck",0.004321898557529471,0.0034545108426313437
NCT00994201,Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response,0.0034784593337584663,0.0036191470928444184
NCT00968435,"Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma",0.003915100763118012,0.0040129939092565835
NCT00911326,Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma,0.004061681309895173,0.002969569585950852
NCT00903461,Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,0.003992053305735656,0.003780351566381975
NCT00038584,A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer,0.003435077557173975,0.003277474789053845
NCT00084318,Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck,0.00402586229323504,0.003997810288776261
NCT00083057,"Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck",0.004153834208294369,0.003836350533653886
NCT00033618,Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck,0.004192765758685053,0.0043261683007199524
NCT00063895,"Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck",0.003928383508426738,0.0034740717753772654
NCT00081211,Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck,0.00446346954010169,0.004097591779093459
NCT00003200,Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck,0.0043888958429186015,0.004293927475109913
NCT00003182,Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck,0.004258288621577422,0.0045022608505391505
NCT00096174,"Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck",0.004040985294701209,0.004003172661533918
NCT00079053,Adjuvant Erlotinib After Completing Chemoradiotherapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004175110279206394,0.0039191257200045845
NCT00076310,OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer,0.002797863001294183,0.0034512254087721733
NCT00073450,Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530),0.004458741476142535,0.0037172423943200926
NCT01427478,Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck,0.003529206315765768,0.004514648784642909
NCT01427205,Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC),0.004876167490221925,0.003934850322242846
NCT01491139,Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck,0.003822972947884973,0.004244244712917031
NCT01465776,Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery,0.0033544056330136194,0.0031124396763709556
NCT01425736,"Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma",0.0034594162950376036,0.0032382236843636145
NCT01437449,"Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",0.004066608556117174,0.004389793821043395
NCT01488318,Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,0.003624655598065945,0.003951758244880302
NCT01458392,Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck,0.004458741476142535,0.003706870563275979
NCT01412229,Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004549056080862169,0.003541818154279359
NCT01449201,PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma,0.006013459396272828,0.003580171360293258
NCT01484847,A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma,0.004318760048604212,0.0037263903068595005
NCT01468896,"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",0.003837311992334712,0.0038496289990526287
NCT01221753,Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study,0.002857456252559841,0.0034894216741931747
NCT01291095,Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma,0.0026364229820839483,0.003326818171090736
NCT01262183,Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus,0.0020123372521311765,0.003455237274676299
NCT01285635,A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck,0.004154101102199444,0.0035394765070403795
NCT01218048,ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma,0.0037725499819947165,0.003062623817773643
NCT02997332,"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma",0.0037698905433592215,0.003754821663594929
NCT02952586,Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),0.004346839850806899,0.004134345955614417
NCT02943044,Quantitative Optical Sensor Findings in Head & Neck Squamous Cell Carcinoma,0.002405589527259646,0.003090595326836804
NCT02949700,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,0.003922589905828664,0.003809521193110063
NCT02985255,Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue,0.0025704628985135335,0.0035568063339695573
NCT02916368,The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma,0.0039027603848619937,0.0030583763294251155
NCT02573493,Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),0.0036812977603365446,0.0034810203189943618
NCT02508246,"WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",0.003870608962587791,0.004078668729873506
NCT02513342,Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma,0.0026804434775128034,0.002367712332385965
NCT02549638,Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma,0.0021101558749774796,0.002562825286274701
NCT02521870,A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,0.003700087390669315,0.003796778024365791
NCT02567422,"VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",0.004288624456698804,0.004309712585071333
NCT00623558,Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC),0.0039032263567320108,0.004997619231677175
NCT00642239,A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma,0.002570595251036456,0.002327540313489691
NCT00652613,Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC),0.003837962007086519,0.003647560171583424
NCT00634777,Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma,0.003605843210674458,0.0043417218611184905
NCT00620139,Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma,0.0034595888317928885,0.00333786489481347
NCT00661427,Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer,0.00357145017328565,0.0036585156319563603
NCT00627835,"Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)",0.0038669214002297557,0.005053850008149135
NCT00358930,A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck,0.005250621616919325,0.0052968566905967195
NCT00343083,"Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)",0.004300164915030686,0.004641717987363012
NCT00363441,A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck,0.0041636895116747355,0.006100907649794262
NCT00304278,Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA),0.00434969786383107,0.004987761475830917
NCT00392665,Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck,0.0034714708738595866,0.003270528603345619
NCT00318890,Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck,0.003766301232297594,0.0035319528458960113
NCT00313027,"Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation",0.0026886656968720347,0.0032463403613618045
NCT00357149,Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS),0.0041979717362646855,0.003809950891875268
NCT00720304,"Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck",0.0035442128968289294,0.003405619953104148
NCT00756444,A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck,0.003678610236858792,0.00341136809163468
NCT00725764,Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck,0.005801531928705553,0.0033482849024038504
NCT00736619,"Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)",0.003910865282849048,0.004069082704873325
NCT00768664,Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer,0.002900891660715051,0.00485460567250718
NCT00707473,"Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses",0.0031480800788860185,0.0035740092347938063
NCT00702481,Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer,0.004208799292734478,0.004382172448279677
NCT00771641,Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck,0.0048560322369921435,0.005635788937725705
NCT00442455,"Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck",0.003937793698509063,0.004078085419381006
NCT00412217,A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer,0.0036948785401662936,0.0034917058650514973
NCT00401323,Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,0.003505413266506125,0.004264407129346697
NCT00459043,Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck,0.003993722892839596,0.004317445399884553
NCT00427102,"MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck",0.004032585893186336,0.004151004089587101
NCT00402545,C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck,0.004459357088626089,0.004424747108162775
NCT00485485,Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer,0.0038156767917596414,0.0032459289574528695
NCT00494182,Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer,0.0035465405800115157,0.0037640892761126614
NCT00474825,Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck,0.003902168130128496,0.004306547360502191
NCT01824823,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,0.0035961766157565885,0.003728051847004993
NCT01807546,Oral Rigosertib for Squamous Cell Carcinoma,0.00455070044883069,0.003116545960523316
NCT01856478,LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,0.0034220131819447655,0.004220706735318359
NCT01823679,Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin,0.0032832566708767058,0.004094332688046327
NCT01827709,Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma,0.005070767940139971,0.0033795297850367314
NCT01872403,Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung,0.002230406484002231,0.0030731707602930955
NCT01950689,NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab),0.004053067382501542,0.003758542802870092
NCT01921426,A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck,0.002761554097278403,0.003621974447876929
NCT01927744,"Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",0.0042958400903961675,0.003726592050889366
NCT01926496,"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%",0.0022612873342999686,0.002734073366358942
NCT01987934,Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma,0.0020079898857693706,0.0026506623276116767
NCT01946230,The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma,0.0025155880011051377,0.002359901606338562
NCT01941966,A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.,0.002831011683588268,0.0034756236859824767
NCT02630264,E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck,0.005378266315108585,0.0031807097985065962
NCT02633800,A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck,0.0037316351660966864,0.0037795014763651108
NCT02641093,Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,0.003697987413535515,0.0036322046638104523
NCT02649530,A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma,0.0049265477481937785,0.003148503290190729
NCT02665702,Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas,0.003312080834813623,0.004175215051860909
NCT02608736,Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid,0.003996146810368942,0.0032295529410630466
NCT02678884,Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study,0.005801531928705553,0.003769300088308611
NCT02684253,"Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",0.003564781079112666,0.0035093192726204717
